Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Published Date: 04 Mar 2024

After a year in a small prospective trial, 91% of cases had local control.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

2.

PNH With Extravascular Hemolysis Approves Factor D Inhibitor.

3.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

4.

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

5.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot